 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--VistaGen Therapeutics, Inc. Nasdaq: VTGN, a late clinical-stage, central nervous system CNS-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in June. Management will be available for one-on-one meetings during these confere 